Bavarian Nordic receives SPA for Stage 3 research of PROSTVAC for advanced prostate cancer Bavarian Nordic A/S declared today that the business has received a letter of concurrence from the U.S. Meals and Medication Administration on a particular Protocol Evaluation for a Stage 3 study necessary for product registration because of its product applicant, PROSTVAC, for the treating individuals with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer tumor. This contract reached with the FDA upon this SPA implies that the Phase 3 research can proceed as designed and, if successful, can form the principal clinical basis of item authorization under a Biologics Licence Program.Related StoriesCHOP's Buerger Center for Advanced Pediatric Treatment celebrates grand openingBoston Kids's Hospital selects Vijay G. EHandover is an operating and practical solution that has been used to take care of over 20,000 handovers for sufferers at BHRUT to date. eHandover is more than just a forward thinking and ground breaking IT solution but also a useful handover methodology which will revolutionise the way we tackle medical center handover later on. The eHandover answer was extremely commended in the ICT category at the NHS Innovations Awards in London 2009. Dr Aklak Choudhury, the inventor of eHandover commented, ‘The eHandover solution is the first to recognize and successfully manage the change gap issue which outcomes in significant communication failure and individual risk during nights and weekends in acute trusts in the united states.